{"id":"https://openalex.org/W12399230","doi":null,"title":"Ion channels as potential targets for the treatment of depression.","display_name":"Ion channels as potential targets for the treatment of depression.","publication_year":2008,"publication_date":"2008-09-01","ids":{"openalex":"https://openalex.org/W12399230","mag":"12399230","pmid":"https://pubmed.ncbi.nlm.nih.gov/18729015"},"language":"en","primary_location":{"id":"pmid:18729015","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18729015","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in drug discovery & development","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5038254883","display_name":"Nicholas J. Lodge","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas J Lodge","raw_affiliation_strings":["Bristol-Myers Squibb, Neuroscience Biology, Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA. Nicholas.Lodge@bms.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Neuroscience Biology, Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA. Nicholas.Lodge@bms.com","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100619887","display_name":"Yu-Wen Li","orcid":"https://orcid.org/0000-0003-1627-8376","observed_orcids":["https://orcid.org/0000-0003-1627-8376"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yu-Wen Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.0096,"has_fulltext":false,"cited_by_count":30,"citation_normalized_percentile":{"value":0.83766129,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"11","issue":"5","first_page":"633","last_page":"41"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.002300000051036477,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ion-channels","display_name":"ion channels","score":0.8009999990463257},{"id":"https://openalex.org/keywords/depression","display_name":"depression","score":0.6980000138282776},{"id":"https://openalex.org/keywords/antidepressant-targets","display_name":"antidepressant targets","score":0.8050000071525574},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.906000018119812},{"id":"https://openalex.org/keywords/nmda-receptor-antagonist","display_name":"NMDA receptor antagonists","score":0.9179999828338623},{"id":"https://openalex.org/keywords/nicotinic-receptor-antagonists","display_name":"nicotinic antagonists","score":0.9330000281333923},{"id":"https://openalex.org/keywords/voltage-gated-calcium-channels","display_name":"voltage-gated calcium channels","score":0.8709999918937683},{"id":"https://openalex.org/keywords/kv7-potassium-channels","display_name":"Kv7 potassium channels","score":0.9369999766349792},{"id":"https://openalex.org/keywords/5-ht3-receptor","display_name":"5-HT3 receptor","score":0.890999972820282},{"id":"https://openalex.org/keywords/p2x7-receptor","display_name":"P2X7 receptor","score":0.9520000219345093},{"id":"https://openalex.org/keywords/depression-like-behavior","display_name":"depression-like behavior","score":0.8130000233650208},{"id":"https://openalex.org/keywords/genetic-association","display_name":"genetic association","score":0.5220000147819519},{"id":"https://openalex.org/keywords/drug-specificity","display_name":"drug specificity","score":0.5889999866485596}],"concepts":[{"id":"https://openalex.org/C50254741","wikidata":"https://www.wikidata.org/wiki/Q62536","display_name":"Ion channel","level":3,"score":0.721159815788269},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.7086622714996338},{"id":"https://openalex.org/C83743174","wikidata":"https://www.wikidata.org/wiki/Q423778","display_name":"Potassium channel","level":2,"score":0.5136935114860535},{"id":"https://openalex.org/C57306754","wikidata":"https://www.wikidata.org/wiki/Q1010629","display_name":"Purinergic receptor","level":3,"score":0.49552738666534424},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.4926169514656067},{"id":"https://openalex.org/C2779570518","wikidata":"https://www.wikidata.org/wiki/Q412256","display_name":"Nicotinic acetylcholine receptor","level":4,"score":0.47682398557662964},{"id":"https://openalex.org/C2776867660","wikidata":"https://www.wikidata.org/wiki/Q1814941","display_name":"Depression (economics)","level":2,"score":0.4714549481868744},{"id":"https://openalex.org/C188987157","wikidata":"https://www.wikidata.org/wiki/Q7030581","display_name":"Nicotinic agonist","level":3,"score":0.45898425579071045},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.44589757919311523},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.41931888461112976},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4005015790462494},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.33079856634140015},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3012480139732361},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.30023542046546936},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.262387752532959},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.25385451316833496},{"id":"https://openalex.org/C169900460","wikidata":"https://www.wikidata.org/wiki/Q2200417","display_name":"Cognition","level":2,"score":0.20936957001686096},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20201128721237183},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.1865381896495819},{"id":"https://openalex.org/C139719470","wikidata":"https://www.wikidata.org/wiki/Q39680","display_name":"Macroeconomics","level":1,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007473","descriptor_name":"Ion Channels","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D007473","descriptor_name":"Ion Channels","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008024","descriptor_name":"Ligands","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D015640","descriptor_name":"Ion Channel Gating","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049990","descriptor_name":"Membrane Transport Modulators","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:18729015","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18729015","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in drug discovery & development","raw_type":"Journal Article"},{"id":"mag:12399230","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18729015","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4205903680","https://openalex.org/W4404230150","https://openalex.org/W4403065652","https://openalex.org/W2123932081","https://openalex.org/W2619412584","https://openalex.org/W1966507947","https://openalex.org/W2093365879","https://openalex.org/W2011195048","https://openalex.org/W4397292091","https://openalex.org/W2382818442"],"abstract_inverted_index":{"Major":[0],"depressive":[1,28],"disorder":[2],"is":[3,65],"highly":[4],"prevalent":[5],"and":[6,33,49,84,105],"remains":[7],"inadequately":[8],"treated.":[9],"Numerous":[10],"studies":[11,83],"have":[12,38,52,76],"demonstrated":[13,39],"that":[14,55,90],"modulation":[15],"of":[16,93,116,135,144],"ion":[17,60,118],"channel":[18,61,75,95],"activity":[19],"can":[20],"reduce":[21],"depression-like":[22,111],"behavior":[23],"in":[24,30,45,126],"animal":[25],"models":[26],"or":[27,129],"symptoms":[29],"humans.":[31,46],"N-Methyl-D-aspartate":[32],"nicotinic":[34],"acetylcholine":[35],"receptor":[36],"blockers":[37],"promise":[40],"as":[41],"potential":[42,67],"antidepressant":[43,68],"agents":[44],"Moreover,":[47],"behavioral":[48],"physiological":[50,128],"findings":[51,87],"provided":[53],"evidence":[54],"the":[56],"more":[57],"recently":[58],"characterized":[59],"TWIK-related":[62],"K+":[63],"channel-1":[64],"a":[66,91,133],"target;":[69],"however,":[70],"drugs":[71],"directed":[72],"at":[73],"this":[74],"yet":[77],"to":[78,140],"undergo":[79],"clinical":[80],"testing.":[81],"Animal":[82],"genetic":[85],"association":[86],"also":[88],"suggest":[89],"number":[92,134],"other":[94],"types,":[96],"including":[97],"voltage-gated":[98],"calcium":[99],"(N-type),":[100],"potassium":[101],"(Kv7),":[102],"serotonin":[103],"5-HT3":[104],"purinergic":[106],"P2X7":[107],"channels,":[108],"may":[109],"influence":[110],"behavior.":[112],"The":[113],"therapeutic":[114],"utility":[115],"some":[117],"channels":[119],"will":[120],"be":[121],"limited":[122],"by":[123],"their":[124],"role":[125],"multiple":[127],"pathophysiological":[130],"processes.":[131],"Nevertheless,":[132],"strategies":[136],"are":[137],"being":[138],"employed":[139],"provide":[141],"improved":[142],"specificity":[143],"action.":[145]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}